System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Daniel Pink is an expert in Oncology at Helios Kliniken (Bad Saarow) (Germany). As of October 2026, ScienceLeadR ranks Daniel Pink in the top 1% of experts worldwide for Sarcoma. Daniel Pink has authored 181 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 13 of them ongoing. SLR score: 1,090 (community average: 125). How the SLR is computed.

LeadR Profile

Daniel Pink Helios Kliniken (Bad Saarow) Germany
1 090 ScienceLeadR Reputation 1090

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Hepatology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026
Source: PubMed

Helios Klinikum Bad Saarow

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 181

Citations

Citations: 7 527 1st author: 13 Last author: 17 Unique author: 0

Main journals

J Clin Oncol 52
Ann Oncol 23
Cancers (Basel) 7
Eur J Cancer 6
Int J Cancer 6

Best Journals

J Clin Oncol 31
Ann Oncol 20
Lancet Gastroenterol Hepatol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Abdominal aortic angiosarcoma following endovascular aneurysm repair: case report and analysis of existing literature.
PMID 42952852 — hemangiosarcoma, aneurysm, transplants, therapeutics, aortic aneurysm, abdominal, endovascular aneurysm repair		Front Surg20260
Variations in surgical strategies and treatment allocation for retroperitoneal sarcomas across German-speaking sarcoma centres.
PMID 42566937 — multiple chronic conditions, sarcoma, histology, therapeutics, medical oncology		Eur J Surg Oncol20260
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.
PMID 42266015 — neoplasms, adenocarcinoma, biomarkers, tryptases, therapeutics, stomach neoplasms, plasma		Int J Cancer20260
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial.
PMID 41997916 — adenocarcinoma, multiple chronic conditions, nivolumab, ipilimumab		Nat Commun20260
Predicting clinically significant prostate cancer with or without digital rectal exam and MRI data using ClarityDX Prostate models.
PMID 41998222 — neoplasms, prostate, biopsy, prostatic neoplasms		NPJ Digit Med20260

Clinical Studies 37

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 3 14
Phase 2 9
N/A 6
Phase 2/Phase 3 6
Phase 1 1
Phase 4 1

By status:

Completed 16
Recruiting 13
Terminated 3
Unknown 2
Active not recruiting 1
Approved for Marketing 1
Not yet recruiting 1

By type:

Interventional 31
Observational 5
Expanded Access 1

By Monocentric/Multicentric:

monocentric 12
multicentric2to4 1
multicentric5to9 3
multicentricup10 21

Main Topics

Ongoing Clinical Trials

13 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A trial to learn how effective and safe datopotamab deruxtecan (Dato DXd) is compared to docetaxel and how well Dato DXd works in adults with advanced or metastatic TROP2 positive non squamous non small cell lung cancer (NS NSCLC)
2024-520101-39-00 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma		Phase 3Not yet recruiting2026
Public Title Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First line Treatment in Participants with Metastatic Leiomyosarcoma
2022-502975-45-00 — leiomyosarcoma, doxorubicin, therapeutics		Phase 3Active not recruiting2023
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First line Treatment of PD L1 high Metastatic Non small Cell Lung Cancer
2024-517780-24-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics		Phase 3Recruiting2025
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00 — sarcoma, ewing, maintenance, sarcoma, therapeutics		Phase 3Recruiting2022
ENGIC 06 (PRODIGE 114) FFCD 2401 FRUQUITAS Randomized phase III trial to compare trifluridine tipiracil Fruquintinib versus trifluridine tipiracil alone for metastatic oeso gastric adenocarcinoma
2025-522395-92-00 — trifluridine, adenocarcinoma		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS